First report of bilateral breast-implant associated anaplastic large cell lymphoma caused by identical T-cell clone

Click to increase image sizeClick to decrease image size

Acknowledgements

The authors sincerely thank Mark Clemens, Elain Jaffe, and Roberto Miranda for their expertise in laboratory workup and critical scientific review.

Disclosure statement

The authors report no conflict of interest. Outside of this scope of work, R.S., N.E.L., M.E.D., B.H.D. and C.M. have no disclosures. A.D. received consulting fees from Seattle Genetics, EUSA Pharma, PER, LOXO, and research support from Roche and Takeda. G.P. is scientific advisory board member for Merck, Tizona, and Trishula Pharmaceuticals and receives research funding from Takeda. S.H. has received research support for clinical trials from ADC Therapeutics, Affimed, Aileron, Celgene, Crispr Therapeutics, Daiichi Sankyo, Forty Seven, Inc., Kyowa Hakko Kirin, Millennium/Takeda, Seattle Genetics, Trillium Therapeutics, and Verastem/SecuraBio. S.H. has consulted, received honorarium from, or participated in advisory boards for Acrotech Biopharma, ADC Therapeutics, Astex, Merck, C4 Therapeutics, Celgene, Cimieo Therapeutics, Daiichi Sankyo, Janssen, Kura Oncology, Kyowa Hakko Kirin, Myeloid Therapeutics, ONO Pharmaceuticals, Seattle Genetics, Shoreline Biosciences, Inc, Takeda, Trillium Therapeutics, Tubulis, Verastem/SecuraBio, and Vividion Therapeutics.